Harrow (NASDAQ:HROW) PT Raised to $55.00 at Lake Street Capital

Harrow (NASDAQ:HROW) had its price target increased by stock analysts at Lake Street Capital from $45.00 to $55.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price target would indicate a potential upside of 9.19% from the stock’s current price.

A number of other brokerages have also recently issued reports on HROW. Craig Hallum increased their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday. B. Riley reaffirmed a “buy” rating and set a $50.00 price objective on shares of Harrow in a report on Thursday, August 29th.

Harrow Trading Up 1.2 %

Shares of HROW stock opened at $50.37 on Friday. The firm has a fifty day moving average of $38.93 and a 200-day moving average of $24.41. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -55.35 and a beta of 0.75. Harrow has a 52-week low of $7.60 and a 52-week high of $51.81. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.12. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. The business had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. On average, equities research analysts forecast that Harrow will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Harrow by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after acquiring an additional 21,253 shares during the last quarter. Woodmont Investment Counsel LLC grew its stake in shares of Harrow by 73.3% during the first quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company’s stock valued at $2,799,000 after purchasing an additional 89,510 shares during the last quarter. Private Capital Management LLC increased its holdings in shares of Harrow by 7.8% in the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after purchasing an additional 217,896 shares in the last quarter. Apis Capital Advisors LLC bought a new position in Harrow in the 2nd quarter worth approximately $1,660,000. Finally, Bank of New York Mellon Corp lifted its holdings in Harrow by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock worth $1,843,000 after buying an additional 12,580 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.